Evidence map›Paper›PMID 32133350›Full record

ReviewFrontiers in bioengineering and biotechnology2020

Targeted Drug Delivery via the Use of ECM-Mimetic Materials.

Jeongmin Hwang, Millicent O Sullivan, Kristi L Kiick

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in bioengineering and biotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 66 citations in OpenAlex.

  1. Article
  2. Ovarian Matrisome Dynamics and αvβ3-Mediated Regulation in Early Follicular Development.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  3. Review
  4. Review
  5. ACS nano · 2026
    Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Biomimetic strategies for the deputization of proteoglycan functions.Frontiers in cell and developmental biology · 2024
    Review
  12. Article
  13. The Chemistry and Biology of Collagen Hybridization.Journal of the American Chemical Society · 2023
    Review
  14. Infantile hemangioma models: is the needle in a haystack?Journal of translational medicine · 2023
    Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Jeongmin HwangDepartment of Biomedical Engineering, University of Delaware, Newark, DE, United States.
Millicent O SullivanDepartment of Biomedical Engineering, University of Delaware, Newark, DE, United States.
Kristi L KiickDepartment of Materials Science and Engineering, University of Delaware, Newark, DE, United States.
University of Delaware · US

Funding

Pilot Research Subproject ProgramP30GM110758 · NIGMS · UNIVERSITY OF DELAWARE · PI PATEL, SANDEEP · 2014 to 2018
$5.8M
Collagen turnover-stimulated gene delivery to enhance chronic wound repairR01AR067247 · NIAMS · UNIVERSITY OF DELAWARE · PI KIICK, KRISTI L, MARGOLIS, DAVID · 2016 to 2019
$1.4M
Collagen-based targeting for improving delivery and efficacy of osteoarthritis drugsR21AR069778 · NIAMS · UNIVERSITY OF DELAWARE · PI KIICK, KRISTI L, PRICE, CHRISTOPHER · 2017 to 2018
$365k
NIAMS NIH HHS R01 AR067247NIAMS NIH HHS R21 AR069778NIGMS NIH HHS P30 GM110758
6 · The paper itself

Abstract

The use of drug delivery vehicles to improve the efficacy of drugs and to target their action at effective concentrations over desired periods of time has been an active topic of research and clinical investigation for decades. Both synthetic and natural drug delivery materials have facilitated locally controlled as well as targeted drug delivery. Extracellular matrix (ECM) molecules have generated widespread interest as drug delivery materials owing to the various biological functions of ECM. Hydrogels created using ECM molecules can provide not only biochemical and structural support to cells, but also spatial and temporal control over the release of therapeutic agents, including small molecules, biomacromolecules, and cells. In addition, the modification of drug delivery carriers with ECM fragments used as cell-binding ligands has facilitated cell-targeted delivery and improved the therapeutic efficiency of drugs through interaction with highly expressed cellular receptors for ECM. The combination of ECM-derived hydrogels and ECM-derived ligand approaches shows synergistic effects, leading to a great promise for the delivery of intracellular drugs, which require specific endocytic pathways for maximal effectiveness. In this review, we provide an overview of cellular receptors that interact with ECM molecules and discuss examples of selected ECM components that have been applied for drug delivery in both local and systemic platforms. Finally, we highlight the potential impacts of utilizing the interaction between ECM components and cellular receptors for intracellular delivery, particularly in tissue regeneration applications.

Indexed as

ECM cell receptorsECM ligandextracellular matrixhydrogeltargeted drug delivery

Identifiers

PMID32133350
PMCPMC7040483
OpenAlexW3007116438

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.